SHERRY SWEIKERT-SMITH: Open Payments
NPI 1831676048 · LEWISTON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$594 in 37 payments from 14 companies in 2025. Trend: 2023 $328 · 2024 $519 · 2025 $594
Food & beverage: $594
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 16 | $145 |
| Teva Pharmaceuticals USA, Inc. | 2 | $66 |
| PFIZER INC. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Novo Nordisk Inc | 3 | $48 |
| Exact Sciences Corporation | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Insulet Corporation | 1 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: TRELEGY ELLIPTA, AUSTEDO XR, NURTEC ODT, REXULTI, GEMTESA, Omnipod, Wegovy, JARDIANCE.
Industry payments across ID — which companies pay providers there.
